Randall Lanier - Chimerix Chief Science Officer
| CMRX Stock | USD 0.89 0.01 1.11% |
Executive
Dr. Randall Lanier, Ph.D., serves as Chief Science Officer of the Company. During his tenure at Chimerix, Dr. Lanier has led teams that designed successful studies of brincidofovir for smallpox, characterized the resistanceactivity profile of brincidofovir for multiple viruses, and explored the potential of the Chimerix chemical library to address unmet medical needs. Recently these efforts led to the identification of a clinical candidate, CMX521, for norovirus, the leading cause of viral gastroenteritis worldwide. Dr. Lanier has nearly 25 years of experience in the discovery and development of antivirals he has focused much of his career on understanding the activity, mechanism, and resistance profiles of nucleoside analogs used for prevention and treatment of viral disease caused by HIV, CMV, adenovirus and poxviruses. Prior to joining Chimerix in 2007, Dr. Lanier held positions of increasing leadership at Burroughs Wellcome, GlaxoWellcome, and GlaxoSmithKline, where he supervised a clinical virologyimmunology laboratory, led teams for drug discovery and licensing opportunity evaluation, served as the clinical virologist on several projects, and supported product differentiation and postmarketing activities since 2017.
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Address | 2505 Meridian Parkway, Durham, NC, United States, 27713 |
| Phone | 919 806 1074 |
| Web | https://www.chimerix.com |
Chimerix Management Efficiency
The company has return on total asset (ROA) of (0.3022) % which means that it has lost $0.3022 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4859) %, meaning that it created substantial loss on money invested by shareholders. Chimerix's management efficiency ratios could be used to measure how well Chimerix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.41 in 2024. Return On Capital Employed is likely to drop to -0.5 in 2024. At this time, Chimerix's Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 316.1 K in 2024, whereas Total Assets are likely to drop slightly above 197 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Shree Patel | Achilles Therapeutics PLC | N/A | |
| Daniel Hood | Achilles Therapeutics PLC | N/A | |
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Mark MBA | X4 Pharmaceuticals | 60 | |
| Marcia Belvin | CytomX Therapeutics | N/A | |
| Shannon Ryan | Assembly Biosciences | N/A | |
| Stacy Rollinger | NextCure | N/A | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| YuWaye MD | CytomX Therapeutics | 56 | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Richard Colonno | Assembly Biosciences | 74 | |
| Tariq Ahmed | Achilles Therapeutics PLC | N/A | |
| Udayan MD | NextCure | N/A | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Robert MBBS | Instil Bio | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.3 |
Chimerix Leadership Team
Elected by the shareholders, the Chimerix's board of directors comprises two types of representatives: Chimerix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chimerix. The board's role is to monitor Chimerix's management team and ensure that shareholders' interests are well served. Chimerix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chimerix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief Officer | ||
| Michael MBA, President CEO | ||
| David CPA, Exec Officer | ||
| Joshua Allen, Chief Imipridones | ||
| Dr MBA, Chief Officer | ||
| Michael Alrutz, interim CEO, Senior Vice President General Counsel | ||
| Pablo MD, Head Affairs | ||
| Roy Ware, Chief Manufacturing and Technology Officer | ||
| Thomas Riga, Chief Officer | ||
| Dr JD, General VP | ||
| Randall Lanier, Chief Science Officer | ||
| Michelle LaSpaluto, Chief Officer |
Chimerix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chimerix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (953.58) % | ||||
| Current Valuation | (54.64 M) | ||||
| Shares Outstanding | 89.94 M | ||||
| Shares Owned By Insiders | 6.62 % | ||||
| Shares Owned By Institutions | 45.90 % | ||||
| Number Of Shares Shorted | 1.52 M | ||||
| Price To Earning | (3.43) X | ||||
| Price To Book | 0.60 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Chimerix Stock Analysis
When running Chimerix's price analysis, check to measure Chimerix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chimerix is operating at the current time. Most of Chimerix's value examination focuses on studying past and present price action to predict the probability of Chimerix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chimerix's price. Additionally, you may evaluate how the addition of Chimerix to your portfolios can decrease your overall portfolio volatility.